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EMERGING MARKET FOR BIOSIMILARS: STATE 
LEGISLATION SHOULD RECONCILE BIOSIMILAR 
SUBSTITUTION LAWS WITH EXISTING LAWS  ON 
GENERIC SUBSTITUTION 
Brian F. King* 
INTRODUCTION 
 
The pharmaceutical industry flourished throughout much of past 
two decades, creating a vast wealth of scientific knowledge and 
revolutionary treatments.  Because of these life-saving therapies, people 
are living longer.  Consequently, our aging population requires more 
medications than ever before.  Who will bear the cost? Insurance 
companies?  The government?  Regardless of who picks up the tab, the 
true cost of healthcare will rest squarely upon the shoulders of the 
American people.  
 The cost of healthcare has become a tremendous concern that 
cannot be ignored.  The US continues to spend a greater percentage of its 
wealth on healthcare than any other industrialized nation.  “In 2012, the 
US spent an average of $8,915 per person on health care, reaching a total 
of $2.8 trillion.”1  Much of this was spent on medications and a growing 
proportion was spent on a new class of therapies called biologics.  As the 
market for biologics continues to grow, it becomes increasingly important 
for state legislation to balance the competing interests of scientific 
innovation and public access.  
 This article is intended to explore the growing market of 
biosimilars and to provide insight into the developing body of law.  It 
should appeal to the interest of healthcare providers and those who have a 
special interest in the future of the pharmaceutical industry.    After 
considering the recent developments in State and Federal law and the 
arguments for and against provisions of state legislation, this paper takes 
the position that, while some additional measures should be considered in 
                                                            
* J.D. Candidate, DePaul University College of Law (2017); Pharm.D., RPH.  Brian King is current 
student at DePaul University College of law in Chicago.  Dr. King holds a PharmD from 
Purdue University and is a practicing Pharmacist in the Chicago area.  He has a special 
interest in drug and biotech patents. 
1 Katherine Wilson, Health Care Costs 101: Slow Growth Persists, California HealthCare 
Foundation, available at, http://www.chcf.org/publications/2014/07/health-care-costs-101. 
(July 2014).   
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state legislation to address the variability and unpredictability of biologics 
and biosimilars, state legislation that erects unnecessary barriers to the 
utilization of biosimilars will increase the cost of healthcare and will stifle 
innovation.  
 Section I provides a background to biologics, with a focus on their 
cost and complexity.  Section II provides a brief overview of the FDA 
drug approval process, and an explanation of the biologic and biosimilar 
approval processes.  Section III discusses the laws for generic substitution 
generally, with a focus on the status of Federal law as well as recent 
developments of State law that have affected the market for biosimilars.  
Section IV introduces the developing role of state laws and provides a 
survey of statements from various interest groups that depict the key 
arguments for and against various components of state legislation.  Section 
V presents implications associated with the new market for biosimilars 
concerning the provision of healthcare and the development of new 
products within the pharmaceutical industry.  After considering the costs 
and benefits of biosimilars, Section VI provides a variety of 
recommendations for healthcare providers, policy-makers, and 
stakeholders in the pharmaceutical industry as the market for biosimilars 
continues to develop and the accompanying body of law attempts to 
reconcile the public’s need for access to high quality biologics and the 
pharmaceutical industry’s incentive to invest in a unpredictable market.  
 
II.  BACKGROUND OF BIOLOGICS 
 
 Each year, the government agency Medicare Payment Advisory 
Commission (“MedPAC”) Biological products, like other drugs, are used 
for the treatment, prevention, or cure of disease in humans.  In contrast to 
traditional chemically synthesized small molecular weight drugs, which 
have a well-defined structure and can be easily characterized, biological 
products are generally derived from living materials, which are complex in 
structure and usually not fully characterized.2  
 Biologic drugs were first developed in the 1980s and were 
considered so specialized that making “generic” versions was thought to 
be nearly impossible.  But over the past 30 years, science has advanced 
                                                            
2 FDA, Biosimilars: Frequently Asked Questions About Therapeutic Biological Products, at, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/%.  
20HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologic 
Applications/ucm113522.htm (hereinafter FDA).   
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dramatically, and as patents on existing biologics began to expire, drug 
companies sought FDA approval for close copies of patented biologics.  
As expected, companies with the original patents initially resisted, 
insisting that their products were so complex that it was impossible to 
copy, but with the passing of time, that argument has lost some of its 
steam.3  
 The FDA and Section 351 of the Public Health Service (PHS) Act 
define a biological product as a “virus, therapeutic serum, toxin, antitoxin, 
vaccine, blood, blood component or derivative, allergenic product, or 
analogous product … applicable to the prevention, treatment, or cure of a 
disease or condition of human beings.”4 
 
A. Complexity of Biologics 
 
 “Biologic medicines are much more complex than traditional 
chemically synthesized drugs. Biologics are manufactured from living 
organisms by programming cell lines to produce desired therapeutic 
substances consisting of large, complex molecules.”5  Because of their 
complexity, it is much more difficult to replicate biologics than traditional 
drugs in the manufacturing process.6  Even the smallest change in the 
manufacturing process can have profound effects on the predictability of a 
product’s efficacy and safety.7  Because of this, it is practically impossible 
to produce a generic version of a biologic that is truly identical.8  
“However, once patents expire for the existing brand-name biologic drugs, 
“biosimilar” medicines can be produced.”9  Unlike generic drugs, 
biosimilars are not therapeutic equivalents of a reference biologic.  Nor are 
they required to seek approval for the all of the indications or dosage 
forms of a reference biologic.  
 Because of the potential differences between biosimilars and the 
reference product, biosimilars are not automatically interchangeable.  
                                                            
3 Sabrina Travernise & Andrew Pollack, F.D.A. Approves Zarxio, Its First Biosimilar Drug, NEW YORK 
TIMES (Mar. 6, 2015). 
4 FDA, Supra note 2. 
5 Richard Cauchi, National Conference of State Legislatures, State Laws and Legislation Related to 
Biologic Medications and Substitution of Biosimilars. (Sep. 10, 2015), available at 
http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-
substitution-of-biosimilars.aspx. 
6 Id. 
7 Id. 
8 Id. 
9 Id. 
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There are a number of considerations that must be addressed before a 
biosimilar can be classified as interchangeable.  The FDA employs a 
“totality of evidence” approach regarding data for approval of a biosimilar, 
meaning that a variety of sources of data can be used for biosimilar 
approval.  Once a biosimilar is approved, its ability to be prescribed and 
dispensed will be dictated by its classification as either “interchangeable” 
or simply “biosimilar.”  Generally, products that are interchangeable can 
be substituted for the reference product, while biosimilars, without more, 
cannot.  
B.  Cost of Biologics 
 
 In 2010, spending on biologics in the U.S. reached an astounding 
$67 billion, representing nearly 30 percent of the overall prescription drug 
market, and displaying a much steeper growth rate than traditional drugs.10  
In 2013, total drug expenditure in the United States was approximately 
$326 billion.11  Of the top 15 drugs, 8 were biologics, representing 9% of 
total drug expenditure.12  In fact, biologic and specialty pharmaceuticals 
are the fastest growing pharmaceutical expense in the US.13  On average, 
biologic drugs are 22 times more expensive than traditional brand name 
drugs.14  
 Numerous strategies have been considered to address the growing 
costs of biologic medications.  One strategy of cost containment has been 
the introduction of competing products known as biosimilars.15  
Biosimilars have the potential to provide considerable cost savings.  The 
US Congressional Budget Office estimated that price competition from 
biosimilars would reduce total expenditures on biologics in the United 
States by $25 billion over a 10-year period, with a decrease in federal 
                                                            
10 Michael Ollove, More States Demand Notification to Use Biosimilar Drugs (Mar. 30, 2015), 
http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2015/3/30/more-states-demand-
notification-to-use-biosimilar-drugs 
11 Univ. of Ill. at Chicago. Coll. of Pharmacy, What is the Status of Biosimilars in the United States? (Nov., 
2014), available at http://dig.pharm.uic.edu/faq/2014/Nov/faq1.aspx. (hereinafter Univ. of Ill.). 
12 Id. 
13 James G. Stevenson, Preparing for Biosimilars: Scientific, Regulatory, and Practice Management Issues 
for Pharmacists (Dec. 12, 2012) (live webcast) available at 
http://www.ashpadvantagemedia.com/downloads/handout_biosimilars.pdf. 
14 Anthony D. So & Samuel L. Katz, Biologics Boondoggle, NEW YORK TIMES, Mar. 7, 2010. 
15 Steven D. Lucio, Evaluating Biosimilars for Formulary Inclusion, PHARMACY PURCHASING & 
PRODUCTS, available at http://www.pppmag.com/article_print.php?articleid=1591. 
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government spending of nearly $6 billion.16   The American Consumer 
Institute Center for Citizen Research estimates savings of $250 billion in 
the US over the next 10 years from just 11 biosimilar products.17  
Therefore, there will be significant pressure in the coming years to utilize 
biosimilars to control health care costs. 
 
 
III.  THE APPROVAL PROCESS OF GENERIC DRUGS AND 
BIOSIMILARS 
 
 Despite the perceived benefits of the readmission penalty, the 
Program has received significant criticism. The Food and Drug 
Administration (“FDA”) regulates traditional drugs under the Food Drug 
and Cosmetic Act (“FD&C Act”).  In contrast, biologics are regulated 
under the Public Health Service (“PHS”) Act.  Compared to the FD&C 
Act, the PHS Act gives the FDA greater regulatory control over the 
manufacturing processes that are uniquely important in the production of 
biologics.  
 The paragraphs that follow provide insight into the framework of 
the approval pathways for traditional drugs and biologic drugs, as well as a 
brief overview and comparison of the approval processes for generic and 
biosimilar counterparts respectively.  
 
 
A.  The Food, Drug, and Cosmetic Act and Hatch-Waxman 
Amendments Regulate the Abbreviated Pathway for Traditional Drugs 
 
 The FD&C Act defines an abbreviated new drug application 
process through which generic manufacturers can obtain approval once 
adequate information is offered to demonstrate bioequivalence with the 
reference product.  Generally, these applications do not require a sponsor 
to conduct clinical trials.  However, additional clinically related data may 
be required for certain products, such as immunogenicity data.  For 
biologics, the PHS Act allows approvals via 351(a) BLA application when 
a sponsor demonstrates the safety, purity, and potency of an 
investigational product through clinical studies.  The new 351(k) pathway 
                                                            
16 S.1695. Biologics Price Competition and Innovation Act of 2007, CONGRESSIONAL BUDGET OFFICE 
(June 25, 2008).  
17 Lucio, supra note 11. 
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will allow for an abbreviated approval of a biosimilar.  However, unlike 
ANDA applications, the biosimilar pathway requires at least one clinical 
study to support product approval.  
 
B.  The Public Heath Service Act and Biologics Price Competition 
and Innovation Act Regulate the Abbreviated Pathway for Biologics 
 
 To help reduce the cost of biologics, the Biologics Price 
Competition and Innovation (BPCI) Act was implemented as part of the 
Affordable Care Act (ACA) to allow for a streamlined approval process 
for biologics that are similar to existing agents, in the expectation of 
reducing the cost of development of these agents.18  Unlike small molecule 
drugs, which are approved under the FD&C Act, the FDA approves most 
biologics under section 351 of the PHS Act.  Compared to the FD&C Act, 
the PHS Act gives the FDA greater regulatory control over the 
manufacturing processes that are especially critical in the production of 
biologics.  Just as the 1984 Hatch-Waxman amendments established the 
abbreviated new drug application (ANDA) for generic medications, the 
BPCI Act created a licensure pathway in which a follow-on product could 
rely on existing scientific knowledge about the originator’s reference 
biologic.19   
 While the intent of the BPCI Act is similar to that of the Hatch-
Waxman Amendments, the approval processes for small molecule drugs 
and biologics differ substantially.  For example, both innovator and 
generic versions of traditional drugs are approved under the FD&C Act, 
whereas biologics are approved under the PHS Act.20   While generic 
approvals primarily consist of bioequivalence studies only, biosimilar 
approvals require at least one clinical trial be conducted to demonstrate it 
is “highly similar” to its reference biologic.21  
 The Patient Protection and Affordable Care Act (“PPACA”) 
created an approval pathway for less expensive generic versions of 
biologic drugs, known as biosimilars, or follow-on biologics.  However, 
new state legislation that could greatly limit the savings from biosimilars 
has sparked a debate similar to the one that followed the passage of 
                                                            
18 Univ. of Ill., supra note 8. 
19 Lucio, supra note 11. 
20 Preparing for Biosimilars, Novation (Nov. 2011), available at 
https://www.novationco.com/media/newsreleases/attachments/preparing_for_biosimilars.pdf(hereinafter 
Preparing for Biosimilars).   
21 Id. 
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legislation that encouraged the development of traditional generic drugs.22  
The enactment of BPCI Act reflected an attempt to balance the interests of 
pharmaceutical manufacturers in recovering the costs of innovation and 
drug development with the need for patients to have access to more 
affordable versions of currently marketed treatments.23  
 Under the BPCI Act, a biological product may be classified as 
“biosimilar” if data show that the product is “highly similar” to or 
“interchangeable” with an already-approved reference biological 
product.24  “Biosimilarity” means that “the biological product is highly 
similar to the reference product notwithstanding minor differences in 
clinically inactive components, and that there are no clinically meaningful 
differences between the biological product and the reference product in 
terms of the safety, purity, and potency of the product.”25  
“Interchangeability” means that the biosimilar must produce the same 
expected clinical results as the reference biologic, and if the biosimilar is 
meant to be given more than once, it should not have a greater risk of 
diminished efficacy or safety concerns than the reference biologic.26  If the 
biosimilar is interchangeable, it may be substituted with the reference 
biologic without intervention by the prescriber.27 
 Given the abbreviated nature of the approval process, biosimilars 
are expected to cost less than the original reference product.28   However, 
whereas the ANDA process requires no additional clinical trial 
information, the complexity of biologic medications necessitates that a 
biosimilar application includes data substantiating that it “does not differ 
                                                            
22 Leigh Purvis, A Sense of Déjà Vu: The Debate Surrounding State Biosimilar Substitution Laws, AARP 
Public Policy Institute (Sept. 2014), available at 
http://www.aarp.org/content/dam/aarp/research/public_policy_institute/health/2014/the-debate-
surrounding-state-biosimilar-substitution-laws-AARP-ppi-health.pdf. 
23 Lucio, supra note 11. 
24 FDA, Biosimilars, (Mar. 6, 2015), at 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplic
ations/therapeuticbiologicapplications/biosimilars/default.htm. 
25 FDA, Christl Leah, FDA’s Overview of the Regulatory Guidance for the Development and Approval of 
Biosimilar Products in the US (Jan. 2, 2015) 1, 6 at 
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApprove
d/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM428732.pdf. 
26 Id. at 8. 
27 Id. 
28 Ramon Hernandez, Biosimilar Products, FDA (June 20, 2013) at 
http://www.piapr.org/clientuploads/11th%20PIA-
FDA%20RegConf%20(June%2020,%202013)/PP/1%20Biosimilar%20Products%20by%20R.%20Hernand
ez.pdf. 
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in a clinically meaningful way from the reference product in terms of 
safety, purity, or potency.”29  
 Biological products are a subset of drugs that are licensed under 
section 351 of the PHS Act.30  Because of the complexity of 
manufacturing and characterizing a biologic product, the PHS Act 
provides for a system of controls over all aspects of the manufacturing 
process.31  It is difficult to characterize and identify the clinically active 
components of a complex biological product, thus such products are often 
defined by their manufacturing processes.  “Since there is a significant 
difference in how biological products are made, the production is 
monitored by the agency during every stage of development to ensure the 
final product turns out as expected.”32 
 The PHS Act allows approval of biologics via a 351(a) BLA 
application when a sponsor demonstrates the safety, purity, and potency of 
an investigational product through clinical studies.33  Prior to the creation 
of the biosimilar pathway under the BPCI Act, otherwise known as a 
351(k) application, the 351(a) BLA application was the only biologic 
approval mechanism available.34   The new 351(k) pathway is significant 
in that it allows for an abbreviated approval of a biosimilar without 
requiring extensive investigation and unnecessary clinical trials.35  
 The purpose of the 351(k) approval process is not to replicate in its 
entirety the clinical development actions of the originator.  Instead, 
through a series of characterizations supported by pharmacokinetic, 
pharmacodynamic, and immunogenicity studies, as well as targeted 
clinical trial data, an applicant can prove that a product so closely 
resembles the originator reference biologic that the biosimilar would be 
expected to behave in a similar fashion in terms of safety and efficacy.36  
The FDA describes this process as a “totality of the evidence approach,” 
                                                            
29 Suzanne M. Sensabaugh, Requirements For Biosimilars and Interchangeable Biological Drugs in the 
United States – in Plain Language 45 DRUG INFO. J. 155, 157 (2011). 
30 FDA, Biosimilars Frequently Asked Questions About Therapeutic Biological Products,  at 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/% 20HowDrugsare 
DevelopedandApproved/ApprovalApplications/TherapeuticBiologic Applications/ucm113522.htm. 
31 Id. 
32 Id. 
33 Preparing for Biosimilars, supra note 16. 
34 Lucio, supra note 11. 
35 Preparing for Biosimilars, supra note 16, at 3. 
36 FDA, Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference 
product (April 2015) at 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM29112
8.pdf. 
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with each phase of biosimilar approval meant to resolve any residual 
uncertainty from previous steps.37 
 A 351(k) application must include information demonstrating that 
the biological product is biosimilar to a reference product.38  The sponsor 
must prove that the biosimilar utilizes the same mechanisms of action for 
the proposed conditions of use, that conditions of use proposed in labeling 
have been previously approved for the reference product, that it has the 
same route of administration, dosage form, and strength as the reference 
product, and is manufactured, processed, packed, or held in a facility that 
meets standards designed to assure that the biological product continues to 
be safe, pure, and potent.39  
 As mentioned, the PHS Act requires that a 351(k) application 
include, among other things, information that demonstrates biosimilarity 
based upon the “totality of evidence.”  This evidence is derived from three 
main sources: analytical studies demonstrating that the biological product 
is “highly similar” to the reference product notwithstanding minor 
differences in clinically inactive components; animal studies (including the 
assessment of toxicity); and a at least one clinical study that is sufficient to 
demonstrate safety, purity, and potency in one or more appropriate 
conditions of use for which the reference product is licensed and for which 
licensure is sought for the biosimilar product.40 
 The BPCI Act also authorizes the FDA to designate certain 
biosimilars as “interchangeable,” meaning that a pharmacist could 
dispense the product in place of the originator without the involvement of 
the prescriber.41   The FDA has stated that while it has authority to grant 
interchangeability status, it does not expect to make such a determination 
upon initial approval of the biosimilar.42   Nevertheless, this subject has 
been contested in many settings, particularly in state legislatures across the 
country as will be discussed infra.  Ultimately, each state’s pharmacy 
practice act will determine the process for implementing interchanges and 
substitutions.  State laws are currently an area of active debate with regard 
to issues such as physician notification, patient consent, documentation, 
and record retention.  For products designated by the FDA as 
                                                            
37 Lucio, supra note 11, at 1. 
38 Christl, supra note 21, at 9. 
39 Id. 
40 Id. at 10. 
41 Sensabaugh, supra note 25, at 3. 
42 FDA, Draft Guidance for industry: Biosimilars: questions and answers regarding implementation of the 
Biologics Price Competition and Innovation Act of 2009 (May 2015) at 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdf. 
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interchangeable with the originator product, determining best practices for 
substitution in the acute-care setting may be relatively straightforward, but 
their implementation in outpatient, specialty pharmacy, and retail 
environments may be much more complex.  
 
C.  Exclusivity under the Biologics Price Competition and 
Innovation Act of 2009 
 
 To address the uncertainty surrounding the approval pathway of 
biologics, Congress passed the Biologics Price Competition and 
Innovation Act of 2009 (BPCIA) as part of health care reform under the 
Patient Protection and Affordable Care Act.  The BPCIA contains a 12-
year exclusivity period for the innovator product during which time the 
FDA will not approve any “follow-on-biologic” that references the 
innovator product.43   These exclusivity protections may actually be more 
useful to innovators than a patent because of the high level of legal 
uncertainty surrounding biologic patent law.  To complicate things further, 
sponsors may not even be able to submit their applications to the FDA for 
at least four years after the innovator receives approval.44  
 Like the Hatch-Waxman act did for generic drugs, the BPCIA 
created a scheme for resolving challenges of patents for innovative 
biologics approved under the PHSA.  This scheme is “designed to enable 
the resolution of patent disputes before a biosimilar enters the market.”45  
Under such a scheme, “the reference product sponsor and biosimilar 
applicant privately exchange information about relevant patents and 
negotiate to identify patents that will be litigated through an immediate 
litigation procedure.”46 
 However, unlike the Hatch-Waxman Act’s patent litigation 
scheme, the scheme created for biosimilars “includes no provision 
preventing FDA from approving a biosimilar if the biosimilar applicant 
indicates it will wait for patent expiry” before entering the market, 
“provides no stay of FDA approval of a biosimilar where a patent 
infringement suit has been brought,” and “provides no special incentive for 
biosimilar applicants to challenge or design around innovator patents.”47  
                                                            
43 42 U.S.C.A. § 262(k)(7)(A) (2010). 
44 42 U.S.C.A. § 262(k)(7)(B) (2010). 
45 Bogaert, et al., Biosimilar regulation: important considerations and global developments, 
PRACTICALLAW.COM (2011), at https://www.practicallaw.com/3-500-9862. 
46 Id.  
47 Id. 
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IV.  LAWS OF THERAPEUTIC SUBSTITUTION 
 
 The practical and legal Pharmacists are given significant 
responsibility by both federal and state governments to help control drug 
costs by making effective generic-substitution choices.  Pharmacists are 
uniquely positioned to leverage their skills and knowledge to into a value-
based therapeutic decision, tailored to a patient’s specific needs.  Equally 
important is a pharmacist’s unique ability to recognize when a generic 
substitution is not appropriate.  Pharmacists should identify opportunities 
for physician consultation to achieve optimal treatment outcomes that 
balance demonstrated safety and cost considerations.  
 The FDA has taken much of the guesswork out of evaluating 
whether two drugs may be substituted for one another with publication of 
the Orange Book.48  According to the FDA's Approved Drug Products 
with Therapeutic Equivalence Evaluations, commonly known as The 
Orange Book, drug products must demonstrate pharmaceutical 
equivalence and bioequivalence to be considered therapeutic equivalents.49  
Therapeutic equivalent drugs are either A-rated (meaning that there are no 
known or suspected bioequivalence problems) or AB-rated (actual or 
potential bioequivalence problems have been resolved with adequate in 
vivo and/or in vitro evidence).50  A-rated drugs may be designated AA, 
AN, AO, AP, or AT, depending on the dosage form.51   This rating is often 
the basis of state-specific substitution laws.  In most states, pharmacists 
cannot substitute “nontherapeutic equivalent products” without first 
consulting the prescriber.52  “Some states allow substitution between 
products as long as state-specific criteria are met, such as having the same 
active ingredient, dosage form, dose, and route of administration.”53  
 For a number of years, before the discussion of biosimilars, at least 
14 states and Puerto Rico have required pharmacists to substitute a generic 
version of the prescribed drug if all prescription requirements are met. 
                                                            
48 Jesse C. Vivian, Generic Substitution Laws, 33 U.S. PHARM. 30, n.6  (2008), 
http://www.uspharmacist.com/content/s/44/c/9787/. 
49 Electronic Orange Book: Approved Products with Therapeutic Equivalence Evaluations, 35th Edition, 
available at FDA.GOV, http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.  
50 Id. at xiii. 
51 Id. 
52 State Regulations on Generic Substitution, 22 PHARM. LETTER/PRESCRIB.220901, n.9 (Sept. 2006). 
53 Id. 
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These laws are not invalidated by biosimilar substitution measures enacted 
as of June 2014.54 
 
A.  Federal Regulations Concerning Interchangeability of 
Biosimilars 
 
 According to U.S.C. Section 262(k)(4) - Safety Standards For 
Determining Interchangeability: 
Upon review of an application submitted under this subsection or 
any supplement to such application, the Secretary shall determine the 
biological product to be interchangeable with the reference product if the 
Secretary determines that the information submitted in the application (or 
a supplement to such application) is sufficient to show that (A) the 
biological product (i) is biosimilar to the reference product; and (ii) can be 
expected to produce the same clinical result as the reference product in any 
given patient; and (B) for a biological product that is administered more 
than once to an individual, the risk in terms of safety or diminished 
efficacy of alternating or switching between use of the biological product 
and the reference product is not greater than the risk of using the reference 
product without such alternation or switch. 
 
B.  Overview of State Legislation Concerning Interchangeability of 
Biosimilars 
 
 As the FDA continues work on implementing the BPCI Act, states 
have considered proposals to restrict substitution of biologic medications.  
Currently, there is concern that traditional statutes regulating the 
substitution of traditional generic drugs may be misapplied to new 
biosimilars that are not identical to the originator.  This has led many 
legislatures to amend older state laws, or add new sections, to address the 
medical and chemical characteristics of biologics and any future generic-
style “follow-on” biologics, biosimilars, or interchangeable biological 
products.55  
 “In the past two years at least 31 states have considered legislation 
establishing state standards for substitution of a ‘biosimilar’ prescription 
                                                            
54 Richard Cauchi, supra note 5. See generally NABP: 2014 Survey of Pharmacy Law, pp. 67-70. Available 
at http://www.ncsl.org/documents/health/Biologics_BiosimilarsNCSLReport2015.pdf. 
55 National Conference of State Legislatures, State Laws and Legislation Related to Biologic Medications 
and Substitution of Biosimilars (Jan. 2015), at 
http://www.ncsl.org/documents/health/Biologics_BiosimilarsNCSLReport_ July_2014.pdf. 
18#2_KING  REVISED .DOC (DO NOT DELETE) 3/19/16 5:55 AM 
2016]   EMERGING MARKET FOR BIOSIMILARS           43 
 
product to replace an original biologic product.”56  Key features of state 
legislation include: prevention by a prescriber of substitution with a 
biosimilar by writing “dispense as written” or “brand medically 
necessary”; consideration for substitution must first be approved as 
“interchangeable” by the U.S. Food and Drug Administration; notification 
of the prescriber of a substitution with a biosimilar; notification of or 
consent by the patient regarding the substitution; and recordkeeping of 
substituted biologics by both pharmacists and prescribers.57  States will be 
required to maintain a public or web-based list of permissible 
interchangeable products.58  In addition, some states require the pharmacist 
to explain the cost or price of the biologic and the interchangeable 
biosimilar and many provide immunity for pharmacists who make a 
substitution in compliance with biologics state law.59  As of the end of 
2014, eight states had enacted such statues, and a number of other states 
had made unsuccessful attempts.60  
 Some states attempted to pass legislation that used different 
approaches such as “right-to-try” legislation, proposing to allow use of 
experimental drugs prior to full FDA approval and economic incentive 
measures intended to expand biologic research and manufacturing in 
individual states.61  Supporters of state proposals believe the ultimate 
decision on substitution should be left to the patient’s prescribing 
physician.  Opponents believe state proposals are restrictive and 
inconsistent with forthcoming national standards, and will increase the 
cost of healthcare.  
 
V.  WHAT ROLE SHOULD STATE LAWS PLAY? 
 
 Not all health policy stakeholders agree on the role of state laws in 
regulating biological and biosimilar medications.  The paragraphs that 
follow provide an overview of some of the considerations put forth by 
various interest groups that support, oppose, or criticize key features of 
state legislation.   
 
A.  Arguments for State Biosimilar Legislation 
                                                            
56 Id. 
57 Id. 
58 Id. 
59 Id. 
60 Id. at 2. 
61 Id. 
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 Biologic drug companies and some patient advocacy groups, 
whose views are often closely aligned with those of the drug industry, 
maintain that the FDA will develop appropriate standards for the approval 
of safe biosimilar and interchangeable biologic products.  However, they 
also believe that additional protections are needed in state substitution 
policies that will “safeguard patient safety and the primacy of the 
physician-patient relationship,” and “ensure transparency and 
communication between patients and their treatment care teams.”62   
 Proponents of state legislation argue that states must step in to 
protect patients that could potentially be exposed to biosimilars without 
their knowledge or consent.  They argue that states should develop new 
statutory protections for patients that provide physicians the authority to 
decide whether interchangeable biologics are appropriate substitutions for 
an originator product.  Some proponents go so far as to argue that the 
FDA’s approach conflicts with the constitutional protections of trade 
secrets.  They argue that the FDA’s approach conflicts with federal laws 
designed to ensure the safety of biologics, presenting serious safety 
concerns and that the duty falls to the states to enact proper legislation 
requiring prior authorization from a physician, and informed consent from 
the patient, before a pharmacist may substitute an biosimilar for an 
innovator product.   
 Biologic drug companies and other state biosimilar legislation 
supporters have also voiced concerns over quality and support the need for 
additional safeguards in state legislation.63  For example, the trade 
organization that represents biologic drug companies argues, “Even though 
interchangeable biologics will be expected to produce the same clinical 
result, it remains the case that patients could react differently to an 
interchangeable biologic than if they were given the innovator product due 
to the complex nature of biologic products and how they work in the 
human body.”64  
 Supporters of state legislation have also raised concerns regarding 
adverse events, arguing that, “everyone should know which biologic a 
patient is taking so it can be used for adverse event reporting.”65  
Supporters of the notification provisions, including some patient advocacy 
                                                            
62 Purvis, supra note 21. 
63 Id. at 2. 
64 Id. 
65 Id. 
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groups and drug manufacturers, insist these provisions protect the patient-
physician relationship and allow prescribers to monitor the patient’s 
experience with the biosimilar.66  
 According to the Institute for Patient Access (IPA), “Biological 
medications differ substantially from conventional drugs and are classified 
differently by the FDA; as a result, laws and regulations developed for 
conventional drugs cannot be applied to biologics. Under current state 
laws, pharmacists may substitute conventional generic drugs for name-
brands without notifying the physician.”67  The IPA asserts that, “even 
with therapeutically interchangeable biologics, underlying differences . . . 
may cause adverse events in some patients or may lead individual patients 
to respond better to one biologic than another,” and emphasizes the 
importance of recordkeeping so that physicians can determine exactly 
which biologic was given to the patient.68  
 According to the Biotechnology Industry Organization (BIO), 
states laws that limit substitution “preserve patient access to accurate 
prescription information, maintain incentives for innovation, and promote 
a competitive market for biologic therapies.”69  The BIO advocates for 
“full transparency” in the substitution process as “patients and their 
physicians should have the right to know what biologic medicine the 
patient receives from the pharmacy.”70  The BIO asserts that state 
biosimilar legislation “properly addresses the need for physician 
communication and represents the interests of those who stand to benefit 
from this new cutting-edge technology.”71 
 
B.  Arguments Against State Biosimilar Legislation 
 
 In contrast, generic drug manufacturers, third party payers, and 
many consumer groups argue that recent state biosimilar substitution 
legislation is “designed to preemptively deter the substitution and use of 
biosimilars,” which frustrates congressional intent to secure cost savings 
for consumers and taxpayers.72  These groups rely on research that shows 
                                                            
66 Mark Lowry, States Grappling With Biosimilar Substitution Laws, Drug Topics: Voice of the Pharmacist, 
(Apr. 2, 2015) at  http://drugtopics.modernmedicine.com/drug-topics/news/states-grappling-biosimilar-
substitution-laws?page=full. 
67 National Conference of State Legislatures, supra, note 54. 
68 Id. 
69 Id. 
70 Id. 
71 Id. 
72 Purvis, supra note 21. 
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“states with patient consent requirements have generic substitution rates 
that are 25 percent lower than states that do not.”73  In addition, some 
notification provisions effectively stifle competition, since the difficulty in 
contacting doctors and the time-consuming recordkeeping will discourage 
pharmacists from substituting less-expensive biosimilars for reference 
biologics.74  An additional concern among those who oppose state 
biosimilar substitution legislation is that requiring pharmacists to inform 
patients and obtain the prescriber’s consent to substitute will exacerbate 
any lingering anxiety and suspicion of generic alternatives, which will 
likely deter biosimilar use.75 
 Opponents also argue that state biosimilar legislation is “extremely 
premature given that the FDA is still in the process of refining the 
biosimilar approval pathway, and that implementing state legislation at 
such an early stage could result in unnecessary conflict between state and 
national laws.”76  Specifically, opponents are concerned that state 
legislation could conflict with federal laws that allow substitution for 
biosimilars that are considered “interchangeable” with their innovator 
counterpart without the involvement of the prescribing doctor. “The FDA 
has also expressed concerns about the effects of state biosimilar 
substitution legislation on access to lower-cost treatments.”77  
 According to America's Health Insurance Plans (AHIP), an effort 
should be made to “remove barriers at the state level that restrict the use of 
biosimilars.”78  AHIP emphasizes that some states have already adopted 
legislation that may restrict the availability of biosimilars before they even 
reach the market, and expresses concern that these proposals “will limit 
patient access to drugs that are not clinically different, yet cost 
substantially less than their brand-name counterparts.”79 
 The Governor of California stated his support for a state bill that 
would “allow interchangeable biosimilar drugs to be substituted for 
biologic drugs, once approved by the FDA.”80  However, the bill would 
have required pharmacists to notify prescribers about which drug was 
dispensed.81  The Governor noted that, while doctors may welcome this 
                                                            
73 Id. 
74 Lowry, supra note 58. 
75 Purvis, supra note 21. 
76 Id. 
77 Id. 
78 Richard Cauchi, supra note 5.  
79 Id. 
80 Id.  
81 Id.  
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information, there remained a significant concern that the requirement 
itself would cast doubt on the safety and desirability of more cost-effective 
alternatives to biologics.82  
 It may come as little surprise that attempts by state legislatures to 
erect barriers to generic substitution have been met with firm opposition 
from the Generic Pharmaceutical Association (GPhA).  The GPhA 
maintains that, “Interchangeability or substitution is the engine that drives 
generic competition.  It is the reason why generic drugs have generated 
savings of $1.06 trillion over the past decade.  The way that FDA deals 
with interchangeability will be directly responsible for the market 
dynamics generated by the biosimilar pathway.”83  The GPhA strongly 
supports automatic substitution legislation that “allows interchangeable 
biologics to be automatically substituted at the pharmacy; upholds the 
current pharmacy practice of automatic substitution; insists on the science-
based FDA determination of interchangeability; and treats all 
interchangeables and their corresponding brand biologics the same once an 
interchangeable is approved.”84  The GPhA supports legislation that 
creates a competitive market for biosimilar products and provides patient 
access to affordable versions of these critical medicines.  
 
VI. IMPLICATIONS OF BIOSILIMAR LEGISLATION 
State biosimilar legislation will have profound effects on many 
aspects of healthcare. There are many rational reasons to support 
legislation that preserves the patient-physician relationship, requires 
diligent record keeping, and respects a patient’s autonomy in choosing his 
or her own treatment plan.  However, if states enact legislation that 
aggressively discourages substitution, there will be a pronounced reduction 
in market competition, and a consequent increase in price.  Alternatively, 
if states enact legislation that fails to provide sufficient stability in a new 
and unpredictable market, pharmaceutical companies will struggle to 
realize a return on their investment, which will discourage innovation.  If 
legislatures fail to protect these investments, innovators will be less likely 
to develop new products to treat challenging diseases.  The ability of state 
legislatures to successfully balance the interests of innovation and access 
will have profound impacts on the future sustainability of the 
                                                            
82 Id. 
83 Id. 
84 Id.  
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pharmaceutical industry and the provision of healthcare.  
 
A.  Effects on the Provision of Healthcare 
 
 State legislation will undoubtedly have significant impacts on the 
availability and delivery of biologics.  Regardless of the challenges that 
may exist when selecting a biologic product or a biosimilar counterpart, 
there are a number of considerations that should be evaluated by 
healthcare providers in order to maximize the value and quality of the 
products and service they deliver.  Physicians, pharmacists, and all 
members of the healthcare team should work together to implement 
evidence-based medicine into formulary with the use of approved 
biologics and biosimilars in appropriate circumstances.  
 
1.  Formulary Management of Biosimilars 
 
 While biosimilars may be relatively new, effective formulary 
management techniques have been around for decades.85  Most 
organizations are familiar with therapeutic interchange protocols for both 
traditional and biologic drugs.  The concept, competencies, and 
infrastructure already exist for the successful formulary management of 
biosimilars.86  Health systems should continue to utilize existing processes 
to evaluate biosimilars for formulary inclusion, carefully consider scope of 
indications for use, and conduct economic analysis, considering costs, 
reimbursement, and patient impact.  
 Generally, the costs of generic drugs are substantially less than their 
brand-name counterparts.  The same has yet to be seen with biosimilars 
because of limited market competition.  “While generic medications 
typically cost about 80% less than brand-name drugs, the savings realized 
by adding biosimilars to formulary may be less substantial.”87   
Biosimilars are expected to cost only about 20 to 30 percent less than the 
originator product.88  Although the savings compared to traditional small 
molecule drugs are seemingly less significant, biosimilars have the 
potential to generate considerable savings and should be thoroughly 
                                                            
85 B. Hawkins, Principles of a Sound Formulary System. Best Practices For Hospital & Health-System 
Pharmacy: Positions and Guidance Documents of ASHP. American Society of Health-System Pharmacists; 
2006:110-113. 
86 Id. 
87 Lucio, supra note 11. 
88 Id. 
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evaluated for formulary inclusion.  
 
2.  Pharmacovigilance and Postmarketing Surveillance 
 
 Postmarketing surveillance will likely be a major responsibility for 
pharmacists and practicing clinicians to identify and report potential safety 
and immunogenicity information. Pharmacovigilance activities are 
essential to assess the ongoing safety and immunogenicity concerns 
associated with the use of biologics.  “Because biologic products . . . are 
by their very nature capable of eliciting immune responses in humans, 
immunogenicity is a focus of safety assessments during development.”89   
“The goal of the immunogenicity assessment is to evaluate potential 
differences between the biosimilar and the reference product in the 
incidence and impact of the human immune response.”90  Post-approval 
data collection on safety data for these drugs is important because there is 
a limited clinical database at the time of a biosimilar’s approval.91   
Another important aspect of post-approval data collection is that the data 
allows researchers to distinguish between different biosimilar products and 
the reference products, making it possible to ascertain which specific 
product a patient has received.  “Because of the potential risks associated 
with biopharmaceuticals, particularly immunogenicity, and the potential 
for clinically meaningful differences between products, there is a need for 
rigorous pharmacovigilance programs to monitor all biopharmaceuticals 
for safety and efficacy issues during the post-approval period.”92  
Manufacturers of biosimilars are required to implement adequate 
postmarketing surveillance mechanisms “to differentiate between the 
adverse events associated with the proposed product and those associated 
with the reference product, including the identification of adverse events 
associated with the proposed product that have not been previously 
associated with the reference product.”  The FDA may also require “a 
postmarketing study to evaluate certain safety risks.”93  
                                                            
89 Walter Reinisch, MD & Josef Smolen, MD, Biosimilar Safety Factors in Clinical Practice. 44 Seminars 
in Arthritis and Rheumatism, S9, S10 (2015) at http://dij.sagepub.com/content/45/2/155.full.pdf+html. 
90 Id. at 12. 
91 H. Mellstedt et al., The Challenge of Biosimilars, 19 ANNALS OF ONCOLOGY 411, 415 (2007). 
92 Id. at 415-16.  Noting, because of the potential risks associated with biopharmaceuticals, particularly 
immunogenicity, and the potential for clinically meaningful differences between products, there is a need 
for rigorous pharmacovigiliance programs to monitor all biopharmaceuticals for safety and efficacy issues 
during the post-approval period. 
93 Lisa A. Haile & Kimberly K. Egan, Regulations for Biosimilars. As biologic drug patents begin to expire, 
generic versions will hit the market—but how will they be regulated? (June 1, 2012) at http://www.the-
scientist.com/?articles.view/articleNo/32152/title/Regulations-for-Biosimilars/. 
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  Pharmacists should leverage their unique position in the healthcare 
delivery chain to participate in postmarketing surveillance.  Pharmacists 
are one of the most accessible healthcare providers for patients to contact 
with concerns regarding safety and efficacy of biologics.  Furthermore, 
pharmacists have access to extensive databases and can utilize existing 
systems to ensure adequate recordkeeping and adverse event reporting.  
 
B.  Effects on the Pharmaceutical Industry 
 
 An additional obstacle for biosimilars involves the particular 
manner in which patents are litigated.94  “Biosimilar legislation provides a 
highly specific process for the identification and negotiation of patents 
between the innovator and the biosimilar applicant.”95  The 351(k) 
pathway likely will be the avenue for most biosimilar approvals.  The 
process requires that a biosimilar sponsor disclose to an innovator critical 
information such as its biologics license application and manufacturing 
process.96  However litigation challenges could drive competitors to 
expedite their entry into the market.97  
 “Substantial uncertainty remains as to whether biosimilar applicants 
would be willing to disclose this information and if the negotiation of 
patents can take place within the time frame described by the 
legislation.”98  Regulatory uncertainty has increased the level of risk in the 
market, which has increased the cost of entry, and resulted in fewer firms 
willing to enter the biosimilar market.  This is especially problematic for 
smaller biotechnology companies whose investments in new biologics 
expose them to serious financial risks.  If courts and policymakers fail to 
protect these investments, innovators will be less likely to develop new 
products to treat challenging diseases.  Uncertainties over the impending 
regulatory framework and defense strategies by name brand biologic 
manufacturers have caused delays in biosimilar development. 
 The FDA should focus on setting guidelines so that more biosimilar 
firms can enter the market.  There is always a lag between application and 
the regulatory decision concerning approval.  It is during this time that the 
FDA can resolve other issues that have arisen, such as naming and state 
substitution laws.  It is important for the FDA to establish definitive 
                                                            
94 Preparing for Biosimilars, supra note 16, at 6. 
95 Id. 
96 Id. 
97 Lucio, supra note 11. 
98 Preparing for Biosimilars, supra note 16.   
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guidelines to minimize uncertainty so that firms will understand the 
process to be undertaken.  Only then can biosimilar competition provide 
the desired benefit to consumers through access to lower priced alternative 
therapies that will allow patients to achieve better medical outcomes.99 
  Notwithstanding the significant potential for biosimilars, their 
establishment in the US market will likely be a slow process.  Stringent 
clinical requirements and a complicated procedure for resolving patent 
disputes are likely to delay market uptake.  Originator patents usually have 
multiple lines of defense, including process patents, which may also slow 
the entry of biosimilars when new markets become available.  Given the 
highly technical issues involved and the lack legal precedent, it is difficult 
to predict how successful the biosimilar market will be in the coming 
years.  
 It will take time for the FDA to believe in the industry’s ability to 
safely and consistently reproduce these complex molecules and for 
physicians overcome their concerns over safety and efficacy.  The 
financial motivation for both payers and patients will also be crucial.  
However, even if regulatory barriers hinder biosimilars initially, the 
financial incentives will ultimately drive acceptance of biosimilar long-
term as entry of leading US companies foster the sector’s credibility.  A 
number of factors will impact the opportunities for cost saving in the US 
including ease of access in the short term, speed of uptake, clarity of 
regulation and, the role of public and private stakeholders.  
  The market exclusivity for the top ten best-selling originator 
biologics is set to expire between now and 2019, and current estimates 
suggest that by 2024, the savings from biosimilars in the US could reach 
$250 billion.  Despite the lingering concerns regarding the safety and 
reproducibility of biosimilars, the market for biosimilars is expected to 
experience significant growth in the coming years, being driven by the 
extensive pipeline and the number of companies becoming involved in this 
area, including some large pharmaceutical companies who are developing 
biosimilar versions of competitor products in order to ensure they are able 
to compete at all levels. 
  Some of the most promising biosimilars in the US include Avastin, 
Epogen, Herceptin, Humira, Intron A, Neulasta, Neupogen, Pegintron, 
Procrit, Remicade, and Rituxin.  In July 2014, the FDA accepted a BLA 
from Sandoz for (Zarxio) filgrastim, as a biosimilar to the reference 
                                                            
99 Joseph P. Fuhr, Biosimilars Can Save Lives and Cost Less, FORBES (Aug. 8, 2014), available at 
http://onforb.es/1ydiWtj. 
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biologic Neupogen.100  In August 2014, Celltrion filed a BLA for 
infliximab (Remsima) as a biosimilar to the reference biologic 
Remicade.101  The FDA recently gave tentative approval to Eli Lilly’s 
“biosimilar” insulin glargine (Basaglar), but will not be available until the 
company resolves patent litigation with Sanofi.102 
 The EU has been dealing with biosimilars since 2006.  The most 
common of which include Omnitrope, Binocrit, Abseamed, Silapo, 
Retacrit, TevaGastrim, Ratiogastrim, Biograstim, and Zarzio.103  Although 
the EU has established and maintained a seemingly functional system of 
approval and regulation for biosimilars, common issues remain to be 
resolved regarding substitutability and interchangeability.  Given that the 
European system has grappled with many of the same issues as the US 
concerning substitutability, interchangeability, and nomenclature, it is 
apparent that the US is not alone in its struggle to implement a cohesive 
system of approval and regulation.  
 
 
VII. RECOMMENDATIONS 
 
Biosimilars are becoming a significant portion of our national 
healthcare spending. Every effort should be made by healthcare 
professionals to remain cost conscious, while maintaining a high level of 
patient care in all settings.  Biosimilars present unique opportunities and 
responsibilities for physicians and pharmacists alike.  Physicians should 
educate themselves about the biologic approval process and remain 
mindful that many biosimilars are approved for only a subset of the 
indications of its reference biologic.  Physicians should work as a part of 
the P&T committee, using established evidence-based processes in the 
evaluation of medications for formulary consideration.  They should 
communicate with patients and pharmacists regarding the goals of therapy 
and clearly indicate the permissibility of substitution.  
 Pharmacists should also act as leaders in the objective evaluation of 
                                                            
100 Sandoz Media Center, FDA Accepts Sandoz Application for Biosimilar Filgrastim, (July 24, 2014), at 
https://www.novartis.com/news/media-releases/fda-accepts-sandoz-application-biosimilar-filgrastim. 
101 Celltrion: What’s New, Celltrion Files for US FDA Approval of Remsima, (Aug. 11, 2014), at 
http://www.celltrion.com/en/company/notice_view.asp?idx=456&code=ennews&intNowPage=1&menu_n
um=&align_year=all. 
102 Jean-Marc Guettier, MD, Department of Health and Human Services, Tentative Approval, (2014), at 
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205692Orig1s000TAltr.pdf 
103 Generics and Biosimilars Initiative, Biosimilars Approved in Europe, (last updated Feb. 27, 2015), at 
http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. 
18#2_KING  REVISED .DOC (DO NOT DELETE) 3/19/16 5:55 AM 
2016]   EMERGING MARKET FOR BIOSIMILARS           53 
 
biosimilars using existing formulary processes.  They should identify 
safety and immunogenicity risks and evaluate such risks with respect to 
cost containment considerations.  Pharmacists should be key players in 
pharmacovigilance and leverage their accessibility to patients as well as 
their access to databases and existing recordkeeping capabilities as a 
conduit of information for government agencies and manufacturers.  
 Given the complexity of biosimilars, greater scrutiny will be 
required of P&T committees than what is traditionally devoted to the 
review of generic medications.104  “P&T committees should use a 
structured, evidence-based process in the evaluation of medications for 
formulary consideration.”105   Brand name products should be when used 
only when indicated and pharmacists should utilize substitution for 
approved interchangeable products under the same principles of existing 
pharmacy law.  
 Products should only be considered for therapeutic interchange 
when there is evidence of therapeutic equivalence, comparable safety 
profiles, significant cost advantages, a clear interchange process, an ability 
to “opt out” in specific circumstances, and an ability to assess outcomes.106  
Although pharmacists can use discretion to substitute interchangeable 
products, they are not only allowed, but are expected to utilize generics 
absent instructions to the contrary.  Decisions should be founded on the 
evidence-based clinical, ethical, legal, social, philosophical, quality-of-life, 
safety, and economic factors that result in optimal patient care.107  
Pharmacists should make a concerted effort to counsel patients on the risks 
and benefits of a given biologic product and should proactively 
communicate with physicians when substitutions are appropriate.108  The 
process of evaluating biosimilars must include physicians, pharmacists, 
and other appropriate health care professionals.  The process should be 
evidence-based and should not be based solely on economic factors.  
 Regarding payment, insurance companies should be expected to 
charge increased rates when patients choose the brand name without 
documented medical necessity. Insurance plans will likely use established 
formulary-review processes to review each drug on its own merit.  If two 
drugs are considered “therapeutically equivalent,” then the plan will 
                                                            
104 Lucio, supra note 11. 
105 American Society of Health-System Pharmacists, ASHP Guidelines on the Pharmacy and Therapeutics 
Committee and the Formulary System, AM J HEALTH-SYS PHARM, 65:1272–83 (2008). 
106 Stevenson, supra note 9. 
107 Id. 
108 Id. 
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decide where on its benefit tier each drug should reside or if it should be 
covered at all.  Plans are likely to use patient financial incentives to drive 
the use of biosimilars.  Insurance companies should implement policies 
that encourage biosimilar utilization, either through prior-authorization 
requirements, or through tiered payment structures that shift a portion of 
the cost of the brand name product back to the patient unless the branded 
product is considered to be medically necessary by the prescriber.  
 State laws should recognize that physicians should have the ability 
to indicate that a patient is not a candidate for generic substitution or 
interchange.  While mandatory notice and pre-approval provisions are 
unnecessary for interchangeable products, physicians should be able to 
prevent substitution when it is determined to be medically necessary.  
Pharmacists should only be permitted to make substitutions for products 
that are approved as “interchangeable.”   Although the pharmacist can play 
a key role in patient education, risk management, and adverse event 
reporting, the prescribing physician is in the best position to evaluate a 
patient’s initial treatment options and must be given a reliable way to 
ensure that the patient receives the precise medication that the prescriber 
intends.  Therefore, even if states do not require pre-authorization, 
physicians must be able to mandate the dispensation of the desired product 
by writing the phrases “dispense as written” or “brand medically 
necessary” on the prescription in order to control the dispensation of a 
brand name product when substitution would be inappropriate.  However, 
as with therapeutic substitutions of traditional small molecule drugs, in the 
absence of an indication to the contrary, pharmacists should be expected to 
utilize the most cost effective treatment available. If a biologic product has 
been approved to be “interchangeable,” it should generally be substituted 
unless the prescriber has indicated that such substitution is impermissible.  
 An effort must be made to reconcile biosimilar substitution laws 
with existing state laws on generic substitution.  Existing substitutions 
laws provide clear and concise rules that enable a physician to prescribe a 
medication with knowledge that the pharmacist will attempt to utilize the 
most economical treatment for the patient.  Physicians are familiar with 
the practice of substitution and are provided with various ways to indicate 
when substitution is impermissible.  In the event that a patient requires a 
specific biologic, physicians can use existing practices to indicate when a 
particular product should be utilized.  State laws should recognize that the 
treatment process involves a number of healthcare providers and should 
enable each provider to contribute to the safe and effective delivery of 
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cost-effective healthcare. 
VIII. CONCLUSION 
 
Biosimilars present significant challenges and opportunities for 
healthcare providers who manage formularies and develop strategies for 
patient care.  It is important to engage in a cost-benefit analysis to examine 
the true impact on patient welfare.  Existing principles of  formulary 
management that are currently employed for traditional small molecule 
drugs should be applied to biosimilars.  Pharmacists and other healthcare 
providers must educate themselves and be prepared to play leadership 
roles in the safe and appropriate introduction of biosimilars into health 
systems.  Healthcare providers should increase their understanding of the 
regulatory pathway for biosimilars, the likely targets for biosimilar 
development, and the clinical communications that will need to occur to 
support appropriate use.  
 Federal legislation has successfully implemented a number of cost 
saving measures designed reduce overall spending on healthcare without 
stifling the development of new medication.  State laws should embrace 
these cost saving measures and should work alongside federal legislation 
to address the concerns of quality and safety without sacrificing dedication 
to cost containment.  As the market for biologics continues to grow, it will 
become increasingly important for state legislation to balance the 
competing interests of scientific innovation and public access.  With 
proper education and the implementation of state laws that support the 
optimal utilization of biosimilars, the US system will be one step closer to 
affordable healthcare.  
 
 
 
 
 
 
 
 
 
 
 
 
18#2_KING  REVISED .DOC (DO NOT DELETE) 3/19/16 5:55 AM 
56              DEPAUL JOURNAL OF HEALTH CARE LAW [VOL. 18.1:31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18#2_KING  REVISED .DOC (DO NOT DELETE) 3/19/16 5:55 AM 
2016]   EMERGING MARKET FOR BIOSIMILARS           57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
